Five of 17 evaluable subjects achieved objective responses, including two confirmed complete responses, in a Phase 2 combination study.
What was announced
BioVaxys Technology Corp. reported positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer.
Among 17 evaluable subjects, five achieved objective responses: two confirmed complete responses and three partial responses. Three responders, including both complete responders, had previously progressed on checkpoint inhibitor therapy.
The company said several patients experienced durable clinical benefit, with one remaining on treatment beyond 18 months, and reported that the regimen was well tolerated.
Source
Read the complete issuer announcement and supporting public materials for full context, assumptions and risk information.
View original source ↗Cornerstone Marketing Inc. provides paid digital media, marketing and news-dissemination services for certain issuers featured in this newsroom. This article is informational and is not investment advice or a recommendation to buy or sell securities.
Read the complete disclosure →